This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D39 (Neoplasm of uncertain or unknown behavior of female genital organs) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date) |
| B. Synonyms | Borderline ovarian tumor, low malignant potential tumor (LMP), uterine smooth muscle tumor of uncertain malignant potential (STUMP), ovarian neoplasm of uncertain behavior, endometrial atypical hyperplasia, vulvar intraepithelial neoplasia (VIN) |
| C. Adult onset | Presents mainly in women of reproductive age in their 20s~50s; borderline ovarian tumors are also common in young women, and STUMP is most common in women in their mid-30s~50s. |
| 1. History | The concept of borderline ovarian tumor was first formalized by Taylor in 1929 and in the 1973 WHO classification, and STUMP was established in the 1994 Stanford classification. |
| 2. Causes | Infertility treatment, endogenous estrogen exposure, BRCA mutations, chronic pelvic inflammation, and endometriosis are the main risk factors. |
| 3. Genetics | Various genetic abnormalities, such as KRAS and BRAF mutations (mucinous and serous borderline), BRCA1/2, TP53, and PTEN, are involved differently by subtype. |
| 4. General epidemiology | Borderline ovarian tumors account for 10~20% of all ovarian neoplasms; STUMP is a rare disease accounting for about 1% of uterine smooth muscle tumors. |
| 5. Pathophysiology | Dualistic model (type I/II): KRAS/BRAF activation (low-grade pathway) versus TP53 mutation (high-grade pathway) is the key pathogenic mechanism of borderline ovarian tumors. |
| 6. Symptoms | Pelvic pain, abdominal distension, irregular vaginal bleeding, dysuria, and infertility are the main symptoms, and many are asymptomatic. |
| 7. Signs | A pelvic mass, ascites, uterine enlargement, vaginal bleeding, and the like may be found on examination, and ovarian lesions may be bilateral. |
| 8. Screening | Regular pelvic ultrasound and CA-125 measurement are recommended in high-risk groups (BRCA mutations, hereditary ovarian cancer syndromes). |
| 9. Diagnosis | Pelvic ultrasound, MRI, serum CA-125 and HE4; final confirmation is by intraoperative frozen section and permanent histopathology. |
| 10. Treatment | Surgery is the first-line treatment; fertility-sparing surgery possible, hysterectomy is standard for STUMP, and chemotherapy has limited efficacy for borderline tumors. |
| 11. Prognosis | 10-year survival rate of borderline ovarian tumors over 90%; long-term follow-up essential because of the possibility of recurrence; STUMP recurrence rate about 10%. |
| 12. Prevention | Oral contraceptives, prophylactic surgery in BRCA carriers, treatment of endometriosis, and regular gynecologic checkups contribute to risk reduction. |
| 13. References | Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art … and 9 other papers |
The history of the concept of neoplasms of uncertain behavior of the female genital organs begins with the clinicopathologic recognition of borderline ovarian tumor (BOT) in the early 20th century. In 1929, Howard Taylor first proposed the concept of "semi-malignant" ovarian tumors, the first description arguing that ovarian neoplasms with a clinical course intermediate between fully malignant and benign tumors are a separate entity. For decades thereafter, various terms (proliferating tumor, borderline malignancy, carcinoma of low malignant potential) were used interchangeably, and it gained international recognition when the World Health Organization (WHO) formally adopted the category "borderline malignancy" in its classification of ovarian tumors in 1973.
Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP) of the uterus was first systematically defined in a 1994 paper by Bell et al. from Stanford University. This study presented criteria classifying uterine smooth muscle tumors as leiomyoma, STUMP, or leiomyosarcoma, using mitotic count, cellular atypia, and the presence of coagulative necrosis as the main criteria. STUMP is a group of tumors with ambiguous histologic features that cannot be included in the conventional dichotomous classification (benign vs malignant), and researchers such as Hendrickson and Oliva have since refined its subclassification.
The molecular pathologic understanding of ovarian epithelial borderline tumors advanced rapidly in the 2000s. The dualistic model of ovarian carcinogenesis (type I/type II) proposed by Shih and Kurman in 2004 positioned borderline tumors as precursor lesions of low-grade serous carcinoma, and this model is now accepted as the standard theoretical framework of ovarian cancer development. The 2014 and 2020 revisions of the WHO classification of tumors of the female genital organs specified the histologic subclassification of borderline tumors (typical borderline, micropapillary borderline, etc.) and the impact on prognosis of whether peritoneal implants are invasive.
In Korea, the frequency of incidental detection of borderline ovarian tumors has increased greatly since the 1990s with the wider spread of ultrasound technology, and according to Health Insurance Review & Assessment Service (HIRA) data, the number of patients registered under the D39 code has been increasing steadily every year. Application of the Special Copayment Reduction system (V193) has reduced the medical cost burden of patients with borderline tumors and enabled systematic follow-up management.
The causes of D39 neoplasms differ by histologic type and site of origin, but hormonal environment, genetic predisposition, and chronic inflammation commonly play important roles.
In borderline ovarian tumors, ovulation-related factors are known to be important risk factors. The increase in risk with a greater number of ovulations (i.e., nulliparity, late first birth, early menarche, late menopause) is explained by the "incessant ovulation hypothesis". The key mechanism is that mechanical injury to the ovarian surface epithelium by repeated ovulation, and the repair process, increase the likelihood of mutation accumulation. Conversely, oral contraceptive use, pregnancy, and breastfeeding lower the risk by suppressing ovulation.
Whether ovulation-inducing agents used in infertility treatment (clomiphene, gonadotropins) increase the risk of borderline ovarian tumors is controversial. Some meta-analyses have reported an association between use of ovulation-inducing agents and increased risk of borderline tumors, but infertility itself is more likely a confounding factor than a cause. Endometriosis is strongly associated with endometrioid and clear cell borderline ovarian tumors.
For STUMP, the exact cause is still unclear, but risk factors similar to those for the development of uterine fibroids are involved. Excessive endogenous estrogen exposure (obesity, exogenous estrogen use), genetic predisposition in Black women, and uterine trauma have been suggested as risk factors. There are also reports that a history of treatment with somatostatin analogues or GnRH analogues, as uterine relaxants, may be partly related to the development of STUMP. Endometrium-related D39 neoplasms (endometrial atypical hyperplasia, endometrial atypical hyperplasia) are closely associated with chronic estrogen exposure, obesity, diabetes, and polycystic ovary syndrome.
The genetic features of borderline ovarian tumors are clearly distinguished by histologic type. In serous borderline tumors (serous BOT), KRAS (codon 12 point mutation) and BRAF V600E mutations are found in about 19~37% and 28~33%, respectively, and these two mutations very rarely occur together. These mutations persistently activate the MAPK (RAS-RAF-MEK-ERK) signaling pathway, promoting cell proliferation. Serous borderline tumors are direct precursor lesions of low-grade serous ovarian cancer and represent the initial stage of the "type I" carcinogenic pathway, which progresses to invasive cancer through gradual accumulation of genetic mutations.
In mucinous borderline tumors (mucinous BOT), KRAS mutations (codon 12 or 13) occur at a high frequency of about 50~75%, and CDKN2A (p16) loss has also been reported. In endometrioid borderline tumors, PTEN inactivation, CTNNB1 (β-catenin) mutation, and MSI (microsatellite instability) are characteristic, which is associated with a developmental pathway through endometriosis. In clear cell borderline tumors, ARID1A mutations are frequently observed.
BRCA1/2 mutations in hereditary ovarian cancer syndromes are more strongly associated with invasive high-grade serous carcinoma than with borderline tumors, but the risk of borderline tumors in BRCA mutation carriers is also reported to be somewhat increased compared with the general population. Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) is associated with an increased risk of endometrioid and clear cell ovarian cancers and borderline tumors.
The molecular features of STUMP are still under study, but MED12 mutations (common in leiomyomas), HMGA2 overexpression, FH (fumarate hydratase) mutations, and TP53 mutations have been reported. TP53 mutations in STUMP may be associated with the potential to progress to leiomyosarcoma and are therefore clinically significant.
Borderline ovarian tumors account for about 10~20% of all ovarian epithelial neoplasms, with an incidence of about 1.8~4.8 per 100,000 population per year in industrialized countries. In the United States, about 5,000~6,000 people are newly diagnosed each year. The incidence in Korea is somewhat lower than in the West, but the frequency of detection is increasing with the spread of health checkups. The median age at onset is about the 40s~50s, about 10~15 years earlier than invasive ovarian cancer. Serous borderline tumors account for about 50~55% of all BOT, and mucinous borderline tumors about 40%.
STUMP is a rare disease accounting for about 1~2% of uterine smooth muscle tumors; its annual incidence is not precisely known, but its share of all uterine smooth muscle tumors is low. It occurs mainly in women aged 35~55, a younger age distribution than leiomyosarcoma. There are also reports that the incidence is higher in women of African descent and that it may have a more aggressive clinical course.
Endometrial atypical hyperplasia (endometrial intraepithelial neoplasia, EIN) is common in postmenopausal women, and its frequency is rising with the growing obese population. In Korea, the incidence of endometrium-related neoplasms is increasing due to westernized dietary habits and the growing obese population. Vulvar intraepithelial neoplasia (VIN) is closely associated with human papillomavirus (HPV) infection, and the incidence of HPV-related VIN is expected to decrease with the spread of HPV vaccination.
The most important concept for understanding the pathogenesis of borderline ovarian tumors is the dualistic model of ovarian carcinogenesis proposed by Shih and Kurman in 2004. In this model, the "Type I" pathway begins in noninvasive borderline tumors and progresses stepwise to low-grade invasive carcinoma, with KRAS and BRAF mutations as the initiating events. The "Type II" pathway is one in which high-grade serous carcinoma arises rapidly from the tubal epithelium through loss of BRCA function and TP53 mutation.
In serous borderline tumors, KRAS/BRAF mutations persistently activate the RAS-ERK signaling pathway that regulates cell differentiation and proliferation. These cells proliferate but have not acquired invasive capacity, and they transform into invasive cancer when additional genetic abnormalities (e.g., TP53 mutation, chromosomal instability) accumulate. Therefore, borderline tumors can be understood as a state of "partial malignant transformation".
The pathogenesis of STUMP is more obscure than that of leiomyosarcoma. It is a state in which cellular atypia appears incompletely along with increased mitotic activity in normal smooth muscle cells, presumed to be due to hormonal influences (downregulation of progesterone receptors), hyperactivation of growth factor (IGF-1, EGF) signaling, or partial abnormalities of apoptotic mechanisms. Overexpression of HMGA2 protein is observed not only in uterine fibroids but also in STUMP, reflecting abnormal regulation of cell proliferation and differentiation.
In endometrial atypical hyperplasia, loss of PTEN function activating the PI3K/AKT/mTOR pathway and promoting proliferation of endometrial epithelial cells has been confirmed as the initial mechanism. Under continued estrogen overexposure, sustained activation of this pathway accelerates increasing cellular atypia and malignant transformation.
The symptoms of D39 neoplasms vary with tumor location and size, hormonal activity, and presence of complications. The most common symptoms of borderline ovarian tumors are pelvic discomfort or pain and abdominal distension. When the tumor is large enough or accompanied by ascites, abdominal enlargement becomes noticeable. When tumor rupture or ovarian torsion occurs, acute abdominal pain accompanied by nausea and vomiting occurs. In premenopausal women, irregular menstruation or amenorrhea may occur, and some are found as the cause of infertility.
Mucinous borderline tumors can grow to very large sizes (some tens of kilograms), so abdominal distension and compressive symptoms (increased urinary frequency, digestive disturbance) are prominent. Serous borderline tumors are often bilateral (about 30~40%), and when accompanied by peritoneal implants, abdominal discomfort is more widespread. About 20~30% are asymptomatic and found incidentally on imaging.
The symptoms of STUMP are similar to those of uterine fibroids, with abnormal uterine bleeding (heavy menstruation, irregular bleeding), pelvic pressure, increased urinary frequency, and pelvic pain as the main symptoms. As an acute symptom, acute abdominal pain due to tumor degeneration (red degeneration, hyaline degeneration) may occur. Endometrial atypical hyperplasia presents mainly with abnormal uterine bleeding (postmenopausal bleeding, irregular bleeding), an important warning symptom for early detection.
On physical examination, borderline ovarian tumors are palpated as unilateral or bilateral adnexal masses on pelvic examination. When the tumor is large, a bulge is seen on abdominal inspection and dullness may be found on percussion. With accompanying ascites, shifting dullness and a fluid wave are positive. When peritoneal dissemination is extensive, induration of the pouch of Douglas may be palpated on rectovaginal examination. However, peritoneal implants in borderline tumors, unlike in invasive cancer, are often noninvasive, so they are difficult to distinguish by physical examination.
In STUMP, the uterus is diffusely enlarged, and a uterine mass with an irregular surface or nodular form may be palpable. Following the convention of expressing uterine size in weeks of gestation, it is commonly palpated at a size of 12 weeks or more. Increased vaginal discharge or abnormal findings on cervical examination may accompany it. In endometrial atypical hyperplasia, physical examination findings are nonspecific, but increased endometrial thickness is confirmed by ultrasound. In patients with postmenopausal bleeding, finding an enlarged, soft uterus strongly suggests an endometrial lesion.
Systematic screening of the general population for D39 neoplasms is not recommended because no survival benefit has been demonstrated to date. The results of the UK UKCTOCS (UK Collaborative Trial of Ovarian Cancer Screening) study (published in 2021) also confirmed that CA-125-based screening combined with transvaginal ultrasound had no significant effect on reducing mortality from ovarian cancer and borderline tumors.
However, targeted follow-up is recommended in high-risk groups. In BRCA1/2 mutation carriers who have not undergone prophylactic salpingo-oophorectomy, the general recommendation is pelvic ultrasound and CA-125 testing every 6 months. In Lynch syndrome carriers, annual endometrial biopsy and pelvic ultrasound are applied for screening for endometrial cancer and related D39 neoplasms. Those with a strong family history (patients with ovarian cancer or borderline tumors among first- or second-degree relatives) also need an individualized screening plan after genetic counseling.
For early detection of endometrial atypical hyperplasia, the standard is to perform endometrial biopsy in all women with abnormal uterine bleeding (especially aged 45 or older, postmenopausal). Regular endometrial ultrasound evaluation is considered in women with high-risk factors such as obesity, diabetes, and tamoxifen use. For screening for vulvar dysplasia (VIN), checking HPV vaccination status and regular gynecologic checkups are important.
The diagnosis of D39 neoplasms is made by a stepwise approach of imaging, serum tumor markers, and final histopathologic confirmation.
Pelvic ultrasound (transvaginal ultrasonography, TVS) is the first-line imaging tool for evaluating ovarian and uterine neoplasms. Borderline ovarian tumors appear as unilocular or multilocular cystic masses, and the presence of internal papillary projections is an important ultrasound finding suggesting a borderline or malignant tumor. The IOTA (International Ovarian Tumor Analysis) classification criteria and Simple Rules are standard tools for systematically assessing the likelihood of benign, borderline, or malignant tumors based on ultrasound features.
MRI is useful for evaluating the septal thickness of multilocular cystic masses, internal solid components, and the presence of peritoneal dissemination, and functional MRI (DWI, dynamic contrast enhancement) is especially helpful in differentiating STUMP from leiomyosarcoma. In intrauterine lesions, decreased ADC values on DWI suggest malignancy. PET-CT is used as an adjunct to evaluate distant metastasis.
Among serum tumor markers, CA-125 is elevated in serous borderline tumors, and HE4 (human epididymis protein 4) is used as a diagnostic aid. The ROMA (Risk of Ovarian Malignancy Algorithm) index combines CA-125 and HE4 values with menopausal status to assess the risk of malignancy. In mucinous tumors, CA19-9 and CEA are useful auxiliary markers.
Final confirmation is made by intraoperative frozen section and permanent histopathology. In histopathologic interpretation, the degree of cellular atypia, mitotic count (/10 HPF or /2mm²), presence of coagulative necrosis, and nuclear atypia are used as criteria to distinguish STUMP from leiomyosarcoma. In immunohistochemistry, the expression patterns of PR, ER, Ki-67, and p53 are used as auxiliary diagnostic markers.
Treatment of D39 neoplasms is individualized according to histologic type, stage, and the patient's wish to preserve fertility.
In borderline ovarian tumors, surgery is the first-line treatment. In women of reproductive age with lesions confined to one side, ovary-sparing surgery (cystectomy or unilateral oophorectomy) is possible, and pregnancy after surgery is possible naturally or through assisted reproduction. The recurrence rate after ovarian cystectomy is higher than after oophorectomy (about 13% vs 4%), but it has the advantage of preserving reproductive function. With bilateral lesions or peritoneal dissemination, or after the reproductive years, bilateral salpingo-oophorectomy and hysterectomy and peritoneal debulking are performed. Chemotherapy has limited efficacy in borderline tumors and is generally not recommended, but platinum-based chemotherapy is sometimes considered when invasive implants are present.
In STUMP, hysterectomy is the standard treatment for women who have completed childbearing. When only myomectomy is performed, the recurrence rate is high, so appropriate surgical management is important. In young women who wish to preserve fertility, a strategy of myomectomy followed by hysterectomy as soon as childbearing is completed is considered. For postoperative follow-up, pelvic MRI every 6 months for 5 years and then annually for 10 years is recommended. In endometrial atypical hyperplasia, hysterectomy is standard for women who have completed childbearing, and for those wishing to preserve fertility, progestin therapy (oral or intrauterine device) is an effective alternative.
The prognosis of borderline ovarian tumors is markedly better than that of invasive ovarian cancer. The overall 5-year survival rate is about 90~95%, and the 10-year survival rate is over 90%. By stage, the 10-year survival rate for stage I is nearly 99%, and favorable survival of around 90% is reported even for stages II-III. However, recurrence can occur even 10~20 years after surgery, so long-term follow-up is essential. Even when it recurs, it mostly recurs as a borderline tumor, and transformation to invasive cancer occurs in about 2~5%.
Poor prognostic factors include the presence of invasive peritoneal implants, a micropapillary pattern, high stage, and incomplete surgical resection. With noninvasive implants, 5-year mortality is 1~3%, whereas with invasive implants it rises to 10~30%. The recurrence rate of STUMP is reported as about 8.7~11%, and since the time to recurrence is long, averaging 3~7 years, long-term follow-up is important. It may recur as leiomyosarcoma, in which case the prognosis may worsen sharply. Risk factors for malignant transformation include the degree of cellular atypia, TP53 mutation, and a high Ki-67 index.
Risk factor control and preventive measures for high-risk groups are key to preventing D39 neoplasms. Oral contraceptive use reduces the risk not only of borderline ovarian tumors but also of invasive ovarian cancer by suppressing ovulation. The risk reduction becomes significant with 5 or more years of use, and the protective effect persists for several years after stopping. Pregnancy and breastfeeding also lower the risk by reducing the number of ovulations.
In BRCA1/2 mutation carriers, risk-reducing salpingo-oophorectomy (RRSO) reduces the risk of ovarian cancer by 85~95% and also greatly lowers the risk of borderline tumors. This surgery is recommended after completion of childbearing at age 35~40 in BRCA1 carriers and at age 40~45 in BRCA2 carriers. Those wishing to preserve fertility before RRSO may consider oocyte or embryo cryopreservation. HPV vaccination is effective in preventing HPV-related vulvar intraepithelial neoplasia and cervical intraepithelial neoplasia, and the 9-valent vaccine is currently available.
To prevent endometrium-related D39 neoplasms, weight management and diabetes control are important. Since obesity is the most important risk factor for endometrial cancer and atypical hyperplasia, weight loss (5% or more) alone can contribute to the reversal of endometrial atypia. Tamoxifen users need regular endometrial evaluation, and replacement with an aromatase inhibitor is considered when possible. In women with endometriosis, appropriate medical and surgical treatment can reduce the risk of developing endometriosis-related ovarian neoplasms.
Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. Oncologist. 2012;17(12):1515-1533. DOI: 10.1634/theoncologist.2012-0139. PMID: 23136143.
Trillsch F, Mahner S, Woelber L, et al. Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a subgroup analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study. Ann Oncol. 2014;25(7):1320-1327. DOI: 10.1093/annonc/mdu119. PMID: 24651399.
Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18(6):535-558. DOI: 10.1097/00000478-199406000-00001. PMID: 8179071.
Zannoni GF, Vellone VG, Arena V, et al. Does malignant transformation of uterine smooth muscle tumour of uncertain malignant potential (STUMP) exist? A clinico-pathological study of 13 cases. Int J Gynecol Pathol. 2010;29(3):257-263. DOI: 10.1097/PGP.0b013e3181bc3680. PMID: 20418769.
Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511-1518. DOI: 10.1016/S0002-9440(10)63708-X. PMID: 15111296.
Kurman RJ, Carcangiu ML, Herrington CS, Young RH (eds). WHO Classification of Tumours of Female Reproductive Organs (4th ed). IARC Press. 2014. ISBN: 978-92-832-2435-3.
Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672-705. DOI: 10.1093/annonc/mdz062. PMID: 30917999.
Hannibal CG, Vang R, Junge J, et al. A nation-wide study of ovarian serous borderline tumors in Denmark 1978-2002: centralized pathology review and overall survival compared with the general population. Gynecol Oncol. 2014;134(2):267-273. DOI: 10.1016/j.ygyno.2014.06.022. PMID: 24983952.
Garg K, Leitao MM Jr, Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009;33(6):925-933. DOI: 10.1097/PAS.0b013e31819cff70. PMID: 19363438.
Prat J (ed). FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol. 2015;26(2):87-89. DOI: 10.3802/jgo.2015.26.2.87. PMID: 25872884.